The key COVID-19 findings in pediatrics, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
36cited sources
21available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY18.1%
Pediatric Long COVID prevalence estimates varied by definition
A systematic review and meta-analysis of 52 cohort studies estimated pooled pediatric Long COVID prevalence at 18.1%. Estimates changed with the definition used.
The pooled estimate came from pediatric cohorts; definition-specific estimates ranged from 16.2% to 21.6%, showing how the chosen definition affected the result.
See the evidence
Pooled pediatric Long-COVID prevalence across 52 cohort studies; estimates varied from 16.2% under NIH criteria to 21.6% under WHO criteria, emphasizing dependence on the adopted definition.
18.1% 95% CI: 13.1-23.6
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Heart involvement was frequent in MIS-C; vaccination was linked to lower risk
80-90%
In a U.S. study, 80-90% of children and adolescents with multisystem inflammatory syndrome in children (MIS-C) had heart involvement. A separate adolescent study reported lower MIS-C risk with BNT162b2 vaccination.
The heart range is descriptive among patients already diagnosed with MIS-C. The reference group for the separate vaccine estimate is not available in this summary, so that magnitude is not featured.
See the evidence
Cardiac Involvement in MIS-C
80-90% 95% CI: 75-95%
Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334-346.
Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):52-58.
Long COVID was associated with school decline after infection
OR 3.5
Children with Long COVID had 3.5 times the odds of school decline compared with children infected with SARS-CoV-2 who did not have Long COVID.
This was a health-record cohort. The figure compares relative odds, not the absolute chance; the timeframe and definition of school decline are not available in this summary.
See the evidence
School decline in children with long COVID vs. infected children without long COVID
OR 3.5 95% CI 1.6-7.9
Case, Abigail et al.. Functional outcomes of children after SARS-CoV-2 infection: An EHR-based cohort study.. Journal of pediatric rehabilitation medicine. 2026.
Omicron was linked to higher odds of severe pediatric COVID-19
OR 3.95
Pediatric patients with Omicron infection had 3.95 times the odds of severe COVID-19 compared with patients infected by pre-Omicron variants.
This is a relative odds comparison, not an absolute risk estimate. The definition of severe disease and the absolute severe-disease rates are not available in this summary.
See the evidence
Omicron variant associated with increased odds of severe COVID-19 disease compared to pre-Omicron variants in pediatric patients
OR 3.95 95% CI: 3.01-5.18
Barter, Thomas T et al.. Impact of SARS-CoV-2 variants and demographic factors on COVID-19 severity in pediatric patients.. BMC infectious diseases. 2026.
Omicron variant associated with increased odds of moderate COVID-19 disease compared to pre-Omicron variants in pediatric patients
OR 2.85 95% CI: 2.31-3.52
Barter, Thomas T et al.. Impact of SARS-CoV-2 variants and demographic factors on COVID-19 severity in pediatric patients.. BMC infectious diseases. 2026.
No clear overall difference in persistent symptoms by virus
At 4-6 weeks, clinician-documented persistent symptoms did not clearly differ among children after RSV, SARS-CoV-2, or influenza infection confirmed by PCR testing.
In this retrospective cohort, patterns varied by age: prevalence was highest after RSV among infants and after SARS-CoV-2 among school-aged children. The overall null result does not prove equivalence.
See the evidence
Clinician-documented persistent symptoms 4-6 weeks after PCR-confirmed infection in children; overall prevalence did not differ significantly among the three viruses.
Bedir, Firat et al.. Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children: A retrospective cohort study.. Medicine. 2026.
Significant virus-by-age interaction in post-acute symptom persistence, with the highest prevalence after RSV among infants and after SARS-CoV-2 among school-aged children.
P < .001
Bedir, Firat et al.. Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children: A retrospective cohort study.. Medicine. 2026.
Maternal COVID-19 was linked to higher odds of preterm birth
In a multinational cohort, pregnant women with COVID-19 had higher odds of preterm birth than pregnant women without COVID-19.
Risk language and odds-ratio statistics are mixed in the available summary, so no magnitude is featured. The evidence came from a multinational cohort.
See the evidence
Preterm Birth Risk (Maternal COVID)
+50-80% OR 1.5-1.8 (95% CI: 1.3-2.1)
Villar J, Ariff S, Gunier RB, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021;175(8):817-826.
Persistent symptoms did not clearly differ overall by virus
At 4-6 weeks, clinician-documented persistent symptoms did not clearly differ among children after RSV, SARS-CoV-2, or influenza infection confirmed by PCR testing.
In this retrospective cohort, age patterns differed: prevalence was highest after RSV among infants and after SARS-CoV-2 among school-aged children. The overall result does not prove equivalence.
Study details & original results
Bedir, Firat et al.. Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children: A retrospective cohort study.. Medicine. 2026.
Clinician-documented persistent symptoms 4-6 weeks after PCR-confirmed infection in children; overall prevalence did not differ significantly among the three viruses.
Significant virus-by-age interaction in post-acute symptom persistence, with the highest prevalence after RSV among infants and after SARS-CoV-2 among school-aged children.
P < .001
Adjusted association between hospitalization and persistent symptoms following pediatric SARS-CoV-2 infection.
aOR 1.9 95% CI: 1.4-2.6
Adjusted association between hypoxemia and persistent symptoms following pediatric RSV infection.
aOR 2.4 95% CI: 1.7-3.3
Adjusted association between age over 6 years and persistent symptoms following pediatric SARS-CoV-2 infection.
Coinfection was not clearly associated with severe pediatric COVID-19
Among hospitalized children at centers using systematic multiplex PCR testing, respiratory viral coinfection was not clearly associated with severe COVID-19.
The reference group for the adjusted comparison is not available in this summary. The result does not prove that coinfection has no effect or that groups were equivalent.
Study details & original results
Di Chiara, Costanza et al.. SARS-CoV-2 Coinfections and Severity in Hospitalized Children With Systematic Testing.. The Pediatric infectious disease journal. 2026.
Respiratory viral coinfection was not associated with increased odds of severe COVID-19 among hospitalized children at centers with systematic multiplex PCR testing.
Influenza admissions had more complications than COVID-19 admissions
Among hospitalized Swiss children, overall complications were more frequent with influenza than with SARS-CoV-2 infection. Lobar pneumonia was also reported with influenza.
This was nationwide prospective surveillance. Only an upper period-specific proportion for lobar pneumonia is available here, and the other components of overall complications are not detailed in this summary.
Study details & original results
Zimmermann, Petra et al.. Comparison of Epidemiology, Risk Factors, Clinical Presentation and Outcomes of COVID-19 and Seasonal Influenza Among Hospitalized Swiss Children: A Nationwide Prospective Surveillance Study.. The Pediatric infectious disease journal. 2026.
Lobar pneumonia among hospitalized children with influenza; the abstract reports only an upper period-specific proportion and states that overall complications were more frequent with influenza (P < 0.001)
Up to 20%
ICU admission among Swiss children younger than 18 years hospitalized with laboratory-confirmed influenza or SARS-CoV-2 infection
Influenza: 10.5% pre-COVID and 11.8% during COVID; SARS-CoV-2: 5.0%-10.3% across variant periods (P = 0.001)
Antibiotic use among hospitalized children with influenza versus SARS-CoV-2 infection
Pediatric Long COVID prevalence depended on its definition
18.1%
Across 52 cohort studies, pooled pediatric Long COVID prevalence was 18.1%; definition-specific estimates ranged from 16.2% to 21.6%.
The review also found no clear difference in Long COVID likelihood between children with at least one dose of a vaccine against SARS-CoV-2 and unvaccinated children. This does not prove equivalence.
Study details & original results
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Pooled pediatric Long-COVID prevalence across 52 cohort studies; estimates varied from 16.2% under NIH criteria to 21.6% under WHO criteria, emphasizing dependence on the adopted definition.
18.1% 95% CI: 13.1-23.6
Likelihood of pediatric Long-COVID among individuals with at least one anti-SARS-CoV-2 vaccine dose versus unvaccinated individuals; the association was not statistically significant.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 21 findingsOriginal results, comparisons and study details.
10 of 10 source groupsFindings stay together with their study.
SOURCE 365 findings
Bedir, Firat et al.. Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children: A retrospective cohort study.. Medicine. 2026.
Significant virus-by-age interaction in post-acute symptom persistence, with the highest prevalence after RSV among infants and after SARS-CoV-2 among school-aged children.
Clinician-documented persistent symptoms 4-6 weeks after PCR-confirmed infection in children; overall prevalence did not differ significantly among the three viruses.
Di Chiara, Costanza et al.. SARS-CoV-2 Coinfections and Severity in Hospitalized Children With Systematic Testing.. The Pediatric infectious disease journal. 2026.
Respiratory viral coinfection was not associated with increased odds of severe COVID-19 among hospitalized children at centers with systematic multiplex PCR testing.
Zimmermann, Petra et al.. Comparison of Epidemiology, Risk Factors, Clinical Presentation and Outcomes of COVID-19 and Seasonal Influenza Among Hospitalized Swiss Children: A Nationwide Prospective Surveillance Study.. The Pediatric infectious disease journal. 2026.
Lobar pneumonia among hospitalized children with influenza; the abstract reports only an upper period-specific proportion and states that overall complications were more frequent with influenza (P < 0.001)
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Pooled pediatric Long-COVID prevalence across 52 cohort studies; estimates varied from 16.2% under NIH criteria to 21.6% under WHO criteria, emphasizing dependence on the adopted definition.
Likelihood of pediatric Long-COVID among individuals with at least one anti-SARS-CoV-2 vaccine dose versus unvaccinated individuals; the association was not statistically significant.
Barter, Thomas T et al.. Impact of SARS-CoV-2 variants and demographic factors on COVID-19 severity in pediatric patients.. BMC infectious diseases. 2026.
Case, Abigail et al.. Functional outcomes of children after SARS-CoV-2 infection: An EHR-based cohort study.. Journal of pediatric rehabilitation medicine. 2026.
Stephenson T, Pinto Pereira SM, Shafran R, et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. Lancet Child Adolesc Health. 2022;6(4):230-239.
Villar J, Ariff S, Gunier RB, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021;175(8):817-826.
Browse the 36 original sourcesThe complete bibliography behind this monitor.
[1]
Bhopal SS, Bagaria J, Olabi B, Bhopal R. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc Health. 2021;5(5):e12-e13.
Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. MMWR Morb Mortal Wkly Rep. 2021;70(49):1710-1716.
Holm M, Espenhain L, Glenthoj J, et al. Risk and phenotype of multisystem inflammatory syndrome in vaccinated and unvaccinated Danish children before and during the Omicron wave. Lancet Child Adolesc Health. 2022;6(7):463-472.
Hippich M, Holthaus L, Assfalg R, et al. A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med (N Y). 2021;2(2):149-163.e4.
Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325(11):1074-1087.
Stephenson T, Pinto Pereira SM, Shafran R, et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. Lancet Child Adolesc Health. 2022;6(4):230-239.
Kikkenborg Berg S, Palm P, Nygaard U, et al. Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health. 2022;6(9):614-623.
Gotzinger F, Santiago-Garcia B, Noguera-Julian A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653-661.
Villar J, Ariff S, Gunier RB, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021;175(8):817-826.
Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):52-58.
Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022;327(4):331-340.
Ouldali N, Toubiana J, Antona D, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. 2021;325(9):855-864.
Son MBF, Murray N, Gee A, et al. Treatments for Multisystem Inflammatory Syndrome in Children: The Best Available Treatment Study (BATS). Lancet. 2021;397(10289):2017-2027.
Behnood SA, Shafran R, Bennett SD, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. J Infect. 2022;84(2):158-170.
Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022;12:9950.
Racine N, McArthur BA, Cooke JE, et al. Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: A meta-analysis. JAMA Pediatr. 2021;175(11):1142-1150.
Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320.
Shuffrey LC, Firestein MR, Kyle MH, et al. Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection. JAMA Pediatr. 2022;176(6):e215563.
Dumitriu D, Emeruwa UN, Hanft E, et al. Outcomes of Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection at a Large Medical Center in New York City. JAMA Pediatr. 2021;175(2):157-167.
Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020;324(3):259-269.
Porritt RA, Binek A, Engel ME, et al. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. J Clin Invest. 2021;131(10):e151520.
Case, Abigail et al.. Functional outcomes of children after SARS-CoV-2 infection: An EHR-based cohort study.. Journal of pediatric rehabilitation medicine. 2026.
Barter, Thomas T et al.. Impact of SARS-CoV-2 variants and demographic factors on COVID-19 severity in pediatric patients.. BMC infectious diseases. 2026.
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Zimmermann, Petra et al.. Comparison of Epidemiology, Risk Factors, Clinical Presentation and Outcomes of COVID-19 and Seasonal Influenza Among Hospitalized Swiss Children: A Nationwide Prospective Surveillance Study.. The Pediatric infectious disease journal. 2026.
Di Chiara, Costanza et al.. SARS-CoV-2 Coinfections and Severity in Hospitalized Children With Systematic Testing.. The Pediatric infectious disease journal. 2026.
Bedir, Firat et al.. Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children: A retrospective cohort study.. Medicine. 2026.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.